220 results on '"Aldape, Kenneth"'
Search Results
2. Long-term survivors of glioblastoma: Tumor molecular, clinical, and imaging findings
3. MODL-32. EGFRVIII OVEREXPRESSION AND LOSS OF MOUSE SPECIFIC CDKN2A IN GLIAL CELLS LEADS TO GLIOMAGENESIS IN A NOVEL MOUSE MODEL
4. PATH-41. INTEGRATED MOLECULAR ANALYSIS REVEALS HYPERMETHYLATION AND OVEREXPRESSION OF HOX GENES TO BE POOR PROGNOSTICATORS IN IDH MUTANT GLIOMA
5. TMIC-82. SPATIAL AND SINGLE-CELL PROTEOMIC LANDSCAPING OF THE HYPOXIC MICROENVIRONMENT IN GLIOBLASTOMA
6. CTIM-19. ONCOLYTIC DNX-2401 VIROTHERAPY PLUS PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA: A PHASE 1/2 TRIAL
7. PATH-56. SUPRATENTORIAL NEUROEPITHELIAL TUMORS WITH NOVEL PLAGL1 FUSIONS: 2 CASE REPORTS
8. CSIG-25. OVERCOMING RESISTANCE TO THERAPIES TARGETING THE MAPK PATHWAY IN GLIOBLASTOMA
9. NIMG-83. ELUCIDATING INTRA-TUMORAL HETEROGENEITY AND DISTINCT RADIOMIC FEATURES IN GLIOBLASTOMA METHYLATION SUBCLASSES
10. EPCO-26. INTRATUMORAL HETEROGENEITY OF GBM IDENTIFIED AND CHARACTERIZED BY A MULTISAMPLING APPROACH AND METHYLATION PROFILING
11. PATH-34. CLINICOPATHOLOGIC CHARACTERIZATION OF DIFFUSE PEDIATRIC-TYPE HIGH-GRADE GLIOMA, H3-WILDTYPE AND IDH-WILDTYPE: AN AGGRESSIVE AND GENOMICALLY COMPLEX GROUP OF TUMORS AFFECTING CHILDREN AND ADULTS
12. CTIM-18. NRG ONCOLOGY STUDY BN007: RANDOMIZED PHASE II/III TRIAL OF IPILIMIUMAB (IPI) PLUS NIVOLUMAB (NIVO) VS. TEMOZOLOMIDE (TMZ) IN MGMT-UNMETHYLATED (UMGMT) NEWLY DIAGNOSED GLIOBLASTOMA (NGBM)
13. PATH-33. MORPHOLOGY, MOLECULAR FEATURES, AND CLINICAL BEHAVIOR OF METHYLATION CLASS PLEOMORPHIC XANTHOASTROCYTOMA
14. PATH-23. CLINICOPATHOLOGIC ANALYSIS OF NOVEL METHYLATION CLUSTERS OF IDH-WILDTYPE DIFFUSE GLIOMAS
15. PATH-49. COMPREHENSIVE RNA-SEQ ANALYSIS REVEALS NOVEL SUBTYPES OF MENINGIOMAS AND PREDICTS PATIENT OUTCOME.
16. PATH-52. MENINGIOMA MOLECULAR GROUPS PREDICT RESPONSE TO SURGERY AND RADIOTHERAPY
17. A novel ARIH1
18. BSBM-07 HIGH-DIMENSIONAL HISTOPATHOLOGIC EVALUATION OF THE HYPOXIC MICROENVIRONMENT IN GLIOBLASTOMA
19. Integrated molecular analysis reveals hypermethylation and overexpression of HOX genes to be poor prognosticators in IDH mutant glioma
20. ZFTA-fused supratentorial ependymoma with a novel fusion partner, DUX4
21. Atypical Neurofibromatous Lesions: Epigenetic Cousins of Other Benign Peripheral Nerve Sheath Tumors?
22. An unusual case of metastatic diffuse midline glioma in an adult
23. First-time identification of a KIF5B-NTRK2 fusion in extraventricular neurocytoma
24. DNA methylation profiling and histologic analysis of sellar TTF-1-positive papillary epithelial tumor supports a novel CNS entity
25. Mutations of FH and IDH may induce gliomagenesis by similar mechanisms
26. BIOM-46. EXPLORING CLINICAL AND PATHOLOGIC CHARACTERISTICS IN GLIOBLASTOMA LONG -TERM SURVIVORS (LTS) VERSUS SHORT-TERM SURVIVORS (STS)
27. TMIC-73. HIGH-DIMENSIONAL HISTOPATHOLOGIC EVALUATION OF THE HYPOXIC MICROENVIRONMENT IN GLIOBLASTOMA
28. PATH-29. BIOLOGIC AND CLINICAL SIGNIFICANCE OF NEOPLASTIC AND MYELOID STATES IN DIFFUSE GLIOMAS
29. TMIC-25. SPATIAL TRANSCRIPTOMIC LANDSCAPE OF DIFFUSE GLIOMA
30. EXTH-88. DOCETAXEL TARGETS AGGRESSIVE METHYLATION PROFILES AND SERVES AS A RADIOSENSITIZER IN HIGH-RISK MENINGIOMAS
31. PATH-26. COMPLEMENTARY CLASSIFICATION APPROACH TO RESOLVE LOW-SCORE RESULTS FROM THE DKFZ METHYLATION CLASSIFIER FOR CNS TUMOR DIAGNOSTICS
32. PATH-30. BIOLOGIC AND CLINICAL SIGNIFICANCE OF NEOPLASTIC AND IMMUNE CELL STATES IN GROUP3 AND GROUP 4 MEDULLOBLASTOMA
33. Glioblastoma, IDH-Wildtype Harboring a KIAA1549::BRAF Fusion: Report of a Case With Comprehensive Molecular Profiling
34. Docetaxel targets aggressive methylation profiles and serves as a radiosensitizer in high-risk meningiomas
35. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial
36. Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions
37. RARE-15. Astroblastoma, MN1 altered comprises two molecularly and clinically distinct subgroups defined by the fusion partners BEND2 and CXXC5
38. MEDB-57.GNAS inactivation as a driver for sonic hedgehog-activated medulloblastoma
39. ETMR-06. Molecular and clinical characteristics of CNS tumors withBCOR(L1) fusion/internal tandem duplication
40. Consensus core clinical data elements for meningiomas (v2021.1)
41. DDRE-39. REPURPOSING CHEMOTHERAPIES AGAINST HIGH-RISK MENINGIOMAS WITH GUIDANCE BY METHYLATION PROFILES
42. EPCO-32. IDENTIFICATION OF PROGNOSTIC CHORDOMA SUBGROUPS USING DNA METHYLATION SIGNATURES IN TISSUE AND PLASMA
43. PATH-18. INTEGRATING TUMOR MICROENVIRONMENT WITH GENOMIC ABERRATIONS AND TUMOR CLASS IN ADULT GLIAL/GLIONEURONAL TUMORS BY DECONVOLUTION OF BULK METHYLATION DATA
44. PATH-26. EVALUATING THE DISTRIBUTION AND PROGNOSIS OF IMMUNE CELL SIGNATURES OF THE TUMOR MICRO-ENVIRONMENT IN DIFFUSE GLIOMAS
45. CTIM-32. IMMUNE CHECKPOINT INHIBITOR NIVOLUMAB IN PEOPLE WITH RECURRENT SELECT RARE CNS CANCERS: RESULTS OF INTERIM ANALYSIS IN A HEAVILY PRETREATED COHORT
46. PATH-39. INTEGRATED MOLECULAR-MORPHOLOGICAL MENINGIOMA CLASSIFICATION: A MULTICENTER RETROSPECTIVE ANALYSIS, RETRO- AND PROSPECTIVELY VALIDATED
47. INNV-27. AN INNOVATIVE VIRTUAL MULTI-INSTITUTIONAL, MULTIDISCIPLINARY NEURO-ONCOLOGY TUMOR BOARD: THE NIH-NOB EXPERIENCE DURING THE COVID-19 PANDEMIC
48. NCOG-34. A DESCRIPTIVE ANALYSIS OF GLIOMATOSIS CEREBRI CASES, COMPARED ACCORDING TO IDH STATUS
49. PATH-46. DIAGNOSTIC IMPACT OF THE CNS TUMOR METHYLATION PROFILING IN A NEUROPATHOLOGY CONSULT PRACTICE
50. PATH-08. PROGNOSTIC IMPLICATIONS FROM LONG-TERM SURVIVORS (LTS) OF GLIOBLASTOMA
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.